LETTER TO THE EDITOR

Interfering with CSE1L/CAS inhibits tumour growth via C3 in triple-negative breast cancer

Mei Ye | Yufei Chen | Jianni Liu | Jiawei Tian | Xunda Wang
Kin Lam Fok | Jianwu Shi | Hao Chen

1Institute of Reproductive Medicine, Medical School, Nantong University, Nantong, China
2Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
3School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China

Correspondence
Hao Chen and Jianwu Shi, Institute of Reproductive Medicine, Medical School, Nantong University, Nantong, China.
Email: chenhao@ntu.edu.cn and jwshi@ntu.edu.cn
Kin Lam Fok, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Email: ellisfok@cuhk.edu.hk

Abstract
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. However, the treatment regimens for TNBC are limited. Chromosome segregation 1-like (CSE1L), also called cellular apoptosis susceptibility protein (CAS), is highly expressed in breast cancer and plays a crucial role in the progression of various tumours. However, the involvement of CAS in TNBC remains elusive. In this study, we showed that the expression of CAS was higher in TNBC samples than in non-TNBC samples in the Gene Expression Omnibus database. Knockdown of CAS inhibited MDA-MB-231 cell growth, migration and invasion. Further RNA-seq analysis revealed that complement pathway activity was significantly elevated. Of note, complement component 3 (C3), the key molecule in the complement pathway, was significantly upregulated, and the expression of C3 was negatively correlated with that of CAS in breast cancer. Lower C3 expression was related to poor prognosis. Interestingly, the expression level of C3 was positively correlated with the infiltration of multiple immune cells. Taken together, our findings suggest that CAS participates in the development of TNBC through C3-mediated immune cell suppression and might constitute a potential therapeutic target for TNBC.

To the Editor,
Breast cancer is the most commonly diagnosed cancer worldwide. Breast cancer is classified into four molecular subtypes—luminal A, luminal B, Erb-B2 overexpressing and basal-like—based on gene expression profiling. The majority of triple-negative breast cancers (TNBCs), which are the most aggressive breast cancers and account for 10%–15% of breast cancers, are of the basal-like subtype. TNBC is characterized by loss of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression. It has an early onset in young women under 40 years old. Despite the use of chemotherapy as the primary treatment strategy, the 5-year survival rate of TNBC is poor due to relapse and metastasis.

Chromosome segregation 1-like (CSE1L), also called cellular apoptosis susceptibility protein (CAS), is involved in nuclear transport. During the shuttling of proteins between the nucleus and the cytoplasm, CAS recycles importin-α from the nucleus to the cytoplasm for its reuse in a new cycle of protein import. This activity facilitates the nuclear import a number of cargo proteins that are known to maintain the repression of several methylated genes, thereby silencing the expression of these genes. CAS also contributes to cell proliferation, apoptosis, migration and cell cycle regulation in multiple cancers. The CAS expression level is also associated with the clinical outcome of cancers. Although several studies have demonstrated the involvement of CAS in breast cancer development, its role in TNBC remains elusive.

Our previous study found that CAS is highly expressed in breast cancers. In the present study, to further investigate the role of CAS in TNBC, we examined the mRNA expression of CAS in TNBC using...
Cellular apoptosis susceptibility (CAS) knockdown inhibited cell growth via the C3 pathway and was associated with the prognosis of triple-negative breast cancer (TNBC). (A) Comparison of the mRNA expression level of CAS between TNBC and non-TNBC samples in the GSE65194 dataset (Probe ID: 201111_at). (B) Representative Western blot of CAS knockdown after lentiviral transduction for 48 and 144 h. shCAS, CAS knockdown; shNC, scramble control. (C) Representative images of the EdU incorporation assay 168 h post transfection. (D) Statistical analysis of MDA-MB-231 cell proliferation as evaluated by an EdU incorporation assay. The values are presented as the mean ± SEM (** P < 0.0001). (E) Western blot analysis of the expression levels of cell cycle proteins in CAS knockdown cells. (F) Colony formation assay to determine the effects of CAS knockdown in MDA-MB-231 cells. The values are presented as the mean ± SEM (** P < 0.001). (G) Representative images of tumours in female BALB/c nude mice bearing MDA-MB-231 cells expressing shNC and shCAS (left) and a photograph of the xenograft mouse model (right). (H) Decreased tumour index (tumour weight/body weight) in the shCAS group. The values are presented as the mean ± SEM (*** P < 0.001). (I) Heatmap analysis of genes related to complement and coagulation cascades. shCAS, CAS knockdown; shNC, scramble control. (J) Real-time PCR validation of the RNA-seq results. (K) Expression analysis of C3 in breast cancer using the GEPIA2 database. (L) Correlation analysis of C3 expression and CAS expression in breast cancer using the TIMER database. (M) Kaplan–Meier analysis of overall survival for breast cancer patients with high (red line, n = 400) and low (blue line, n = 400) C3 mRNA expression as determined in the GEPIA2 database. (N) Schematic diagram of CAS regulates cell proliferation and C3 singling pathway in TNBC cells.
three datasets from the Gene Expression Omnibus database. The expression of CAS was significantly higher in TNBC than in other breast cancer types (Figure 1A, Figure S1A,B).

To investigate the functions of CAS in TNBC, we stably knocked down CAS in MDA-MB-231 cells by lentiviral transduction of CAS shRNA (shCAS) or scramble control shRNA (shNC) (Figure 1B). The CCK8 assay results showed that knockdown of CAS significantly inhibited the growth of MDA-MB-231 cells, with a comparable number of viable cells 168 hours after transduction (Figure S1C). The growth arrest in CAS knockdown cells was attributed to the decrease in cell proliferation, as reflected by the significant decrease in EdU incorporation assay (Figure 1C,D). It is well known that disruption of the cell cycle leads to cell proliferation arrest. We further analysed the expression levels of key cell cycle regulators, such as p53, cyclin D1 and cyclin B1. We found that in the shCAS group, p53 was significantly upregulated 6 days after transduction (Figure 1E, Figure S1D), while the expression of cyclin D1 and cyclin B1 was significantly decreased, indicating cell cycle arrest. In line with the growth arrest, knockdown of CAS abolished colony formation (Figure 1F). Of note, knockdown of CAS in MCF-7 cells, derived from another subtype of breast cancer, had no effect on the expression of cyclin B1 in our previous study or on the expression of p53 in a study by Tanaka et al. The differential response of cyclins and p53 toward knockdown of CAS suggested the differential roles of CAS in cell proliferation in TNBC compared to non-TNBCs.

Since CAS is also known to promote metastasis in melanoma, we examined the migration and invasion of CAS knockdown MDA-MB-231 cells. The results showed that loss of CAS significantly inhibited migration and invasion (Figure S1E-G). To further evaluate the effect of CAS on the tumorigenicity of TNBC cells in vivo, shNC or shCAS MDA-MB-231 cells were injected into the bilateral armpits of athymic nude mice. The tumour volume was significantly decreased in the shCAS group (Figure 1G,H, Figure S1H). These results indicated that CAS plays an important role in the growth, metastasis and tumorigenicity of TNBC cells.

To decipher the molecular mechanisms underlying the regulation of tumour progression by CAS in TNBC, we performed RNA sequencing to analyse the transcriptome of CAS knockdown MDA-MB-231 cells. A total of 8325 differentially expressed genes with a fold change ≥2 and P value < 0.05 were identified: 3970 genes were upregulated and 4355 were downregulated in the shCAS group compared to the shNC group (Figure S2A). We subjected differentially expressed genes with a fold change ≥8 and P value < 0.05 to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. GO term enrichment analysis revealed that regulation of epithelial cell apoptotic process, ‘peptide hormone processing’, ‘negative regulation of epithelial cell apoptotic process’ and ‘regulation of endothelial cell apoptotic process’ were the top four enriched terms (Figure S2B). Of note, KEGG pathway enrichment analysis revealed enrichment of genes involved in the complement and coagulation cascades (Figure S2C), and four genes associated with this pathway were upregulated in CAS knockdown cells (Figure 1I). Real-time qPCR confirmed significant upregulation of complement component 3 (C3), complement factor I (CFI), fibrinogen gamma chain (FGG) and F2R-like thrombin or trypsin receptor 3 (F2RL3) in CAS knockdown cells (Figure 1J). C3 is a well-characterized component of the complement system. The complement system is a component of innate immunity that participates in the defence against invading pathogenic microorganisms and eliminates damaged host cells and cancer cells. Activation of the key players C3a and C5a attracts immune cells to sites of complement activation and triggers an inflammatory response. Interestingly, cancer cells also secrete complement proteins that regulate the tumour microenvironment and promote tumour growth and metastasis. In addition, TNBC cells have recently been shown to secrete complement proteins. Therefore, we further investigated the role of C3 in breast cancer with the Gene Expression Profiling Interactive Analysis 2 (GEPIA2) database and the Tumour Immune Estimation Resource (TIMER) database, a database for the analysis of tumour-infiltrating immune cells. In contrast to CAS, which exhibited significantly increased expression in breast cancer, C3 was significantly downregulated in breast cancer (Figure 1K), and we identified a negative correlation of CAS expression with C3 expression in breast cancer in the TIMER database (Figure 1L). Lower expression of C3 was significantly associated with poorer overall survival and disease-free survival (Figure 1M, Figure S2D). In addition, C3 expression was negatively correlated with tumour purity and positively correlated with infiltration of macrophages (r = 0.323, P = 2.96e-25), neutrophils (r = 0.549, P = 6.83e-76), dendritic cells (r = 0.566, P = 1.42e-81), B cells (r = 0.389, P = 1.48e-36), CD8+ T cells (r = 0.383, P = 2.08e-35) and CD4+ T cells (r = 0.547, P = 3.66e-76) (Figure S2E). These results suggest that the high C3 expression stemming from knockdown of CAS may attract immune cells to the tumour microenvironment.

In summary, we found that knockdown of CAS inhibited cell proliferation and metastasis as well as tumour growth, and we identified a novel inflammatory C3 pathway regulated by CAS in TNBC (Figure 1N). Interestingly, activation of C3 can promote or inhibit tumour progression in a cell type-specific manner in cancers. The contrasting roles of C3 have also been observed in breast cancer: C3 deficiency in Her2/neu transgenic mice increased cancer metastasis, indicating that C3 exerts a tumour-suppressive effect, while tumour-derived C3 disrupted the blood–cerebrospinal fluid barrier and promoted cancer growth. In the present study, our results showed significant inhibition of cell proliferation after knockdown of CAS, accompanied by a significant increase in C3 expression in TNBC, indicating that C3 plays a tumour-suppressive role in TNBC. In agreement with the experimental data, database analysis revealed down-regulation of C3 in breast cancer, and lower C3 expression was associated with poor prognosis. Taken together, the present findings revealed the CAS-dependent inflammatory C3 pathway in TNBC, which might provide new targets for TNBC therapy. Further studies are warranted to determine the detailed mechanism by which CAS regulates the C3 pathway in TNBC.
ACKNOWLEDGEMENTS
This work was supported in part by grants from the National Natural Science Foundation of China (81871202 to Hao Chen), the Natural Science Foundation of Nantong (JC2021081 to Jianwu Shi), Lo Kwee Seong Start Up Fund and startup R&D funding from Nantong University (03083011 and 03083028 to Hao Chen, 135419631032, TDYX2021021 to Jianwu Shi).

FUNDING INFORMATION
National Natural Science Foundation of China, Grant/Award Number: 81871202; Nantong University, Grant/Award Number: 03083028, 03083011, 135419631032; The Natural Science Foundation of Nantong, Grant/Award Number: JC2021081; Lo Kwee Seong Start Up Fund

CONFLICT OF INTEREST
The authors declare that there are no conflicts of interest.

AUTHOR CONTRIBUTIONS
Hao Chen and Jianwu Shi conceived and designed the experiments. Mei Ye, Yufei Chen, Jianni Liu, Jiawei Tian and Xunda Wang performed the experiments and analysed the data. Mei Ye and Kin Lam Fok wrote the manuscript. Hao Chen, Kin Lam Fok and Jianwu Shi revised the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Hao Chen https://orcid.org/0000-0001-8319-8101

REFERENCES
1. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-2223.
2. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61.
3. Kutay U, Bischoff FR, Kostka S, Kraft R, Görlich D. Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor. Cell. 1997;90(6):1061-1071.
4. Dong Q, Li X, Wang CZ, et al. Roles of the CSE1L-mediated nuclear import pathway in epigenetic silencing. Proc Natl Acad Sci USA. 2018;115(7):E4013-E4022.
5. Alnabulsi A, Agouni A, Mitra S, et al. Cellular apoptosis susceptibility (chromosome segregation 1-like, CSE1L) gene is a key regulator of apoptosis, migration and invasion in colorectal cancer. J Pathol. 2012;228(4):471-481.
6. Liu C, Wei J, Xu K, Sun X, Zhang H, Xiong C. CSE1L participates in regulating cell mitosis in human seminoma. Cell Prolif. 2019;52(2):e12549.
7. Ye M, Han R, Shi J, et al. Cellular apoptosis susceptibility protein (CAS) suppresses the proliferation of breast cancer cells by upregulated cyp24a1. Med Oncol. 2020;37(5):43.
8. Tai CJ, Shen SC, Lee WR, et al. Increased cellular apoptosis susceptibility (CSE1L/CAS) protein expression promotes protrusion extension and enhances migration of MCF-7 breast cancer cells. Exp Cell Res. 2010;316(17):2969-2981.
9. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153-166.
10. Tanaka T, Ohkubo S, Tatsuono I, Prives C. hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell. 2007;130(4):638-650.
11. Liao CF, Luo SF, Li LT, Lin CY, Chen YC, Jiang MC. CSE1L/CAS, the cellular apoptosis susceptibility protein, enhances invasion and metastasis but not proliferation of cancer cells. J Exp Clin Cancer Res. 2008;27:15.
12. Roumenina LT, Daugan MV, Petitprez F, Sautès-Fridman C, Fridman WH. Context-dependent roles of complement in cancer. Nat Rev Cancer. 2019;19(12):698-715.
13. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785-797.
14. Zhang R, Liu Q, Li T, Liao Q, Zhao Y. Role of the complement system in the tumor microenvironment. Cancer Cell Int. 2019;19:300.
15. Li S, Li X, Yang S, et al. Proteomic landscape of exosomes reveals the functional Contributions of CD151 in triple-negative breast cancer. Mol Cell Proteomics. 2021;20:100121.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Ye M, Chen Y, Liu J, et al. Interfering with CSE1L/CAS inhibits tumour growth via C3 in triple-negative breast cancer. Cell Prolif. 2022;55(5):e13226. doi:10.1111/cpr.13226